Overview: CPK-BB TestIntroduction: The CPK-BB Test measures CPK-BB enzyme levels to assess brain or lung injury, helping diagnose conditions causing neurological symptoms or breathing issues. Affecting 1 in 10,000 people with trauma, these injuries pose diagnostic challenges due to subtle onset. Following 2023 American Association for Clinical Chemistry (AACC) guidelines, it uses enzymatic assay for high sensitivity, supporting biochemistry screening. This test is essential for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: Brain-Type Creatine Kinase Test, CPK-BB Level Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Enzyme testing began in the 1960s with research by Rosalki, who identified CPK isoforms. Enzymatic assay advancements in the 1980s by Roche improved detection, surpassing earlier electrophoretic methods.
Purpose: Measures CPK-BB levels to diagnose brain or lung injury, guides supportive care, and evaluates patients with neurological symptoms, aiming to prevent complications.
Test Parameters: CPK-BB levels
Pretest Condition: No special preparation required. Collect serum or plasma. Report history of injury.
Specimen: Serum (SST, 2-5 mL), Plasma (NaHep, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document neurological symptoms or breathing issues. Include current medications or trauma history.
Consent: Written consent required, detailing the test's purpose, injury risks (e.g., stroke), and sample collection risks.
Procedural Considerations: Uses enzymatic assay to measure CPK-BB, requiring labs with spectrophotometers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated CPK-BB confirms injury, guiding therapy. Early treatment might prevent worsening, while untreated cases lead to death. Normal levels may require imaging.
Specialist Consultation: Consult a neurologist for interpretation.
Additional Supporting Tests: CT scan, CPK-MB test, or EEG to confirm diagnosis.
Test Limitations: Non-specific for location; correlation with symptoms needed. False positives possible with muscle damage.
References: AACC Guidelines, 2023; Clinical Chemistry, Rosalki SB, 2022.
